1,721,406 research outputs found

    Esophageal achalasia: A mistery with different solutions

    No full text
    Achalasia is still an intrigning "mistery" and although different "solutions" are available, the definitive "cure" is missing. The present review summarizes the available data in the literature regarding drug therapy, the use of botolinum toxin intrasphinteric injection, and pneumatic dilation while direct comparative information is still lacking, some guidelines on therapeutic options can be given

    Genetics and ulcerative colitis: What are the clinical implications?

    No full text
    Substantial progress has been made in the last years in characterizing the susceptibility genes involved in IBD pathogenesis, especially for Crohn's disease. Although some genetic factors associated with Crohn's disease also predispose individuals to ulcerative colitis, markers specific only for ulcerative colitis have been found. Recent genomewide association studies in ulcerative colitis have identified several new loci, and suggested many new potential pathways. The identified susceptibility genes and their variants could be useful to predict disease course and to improve stratification of patients, when correlated with other subphenotypes. Moreover, understanding the biological pathways involved in the disease could lead to the development of new treatments and molecules that specifically target such pathways, discover different therapeutic approaches and eventually progress to personalized treatment. © 2011 Bentham Science Publishers Ltd

    Pharmacological options in achalasia

    No full text
    Achalasia is a common primary oesophageal motor disorder. Treatment has been based traditionally on a surgical approach: however, there is new evidence that some medical strategies may be of benefit. The purpose of the present article was to review the current medical management of achalasia. A Medline search identified original articles and reviews published in the English-language literature between 1966 and 1998. This search has revealed that the pharmacological treatment of achalasia is limited to some subgroups of patients (for example, early stages of the disease and elderly patients), and that nitrates, nifedipine, and botulinum toxin are the best studied and most effective compounds
    corecore